243 related articles for article (PubMed ID: 18791333)
41. Defining orphan conditions in the context of the European orphan regulation: challenges and evolution.
O'Connor DJ; Sheean ME; Hofer MP; Tsigkos S; Mariz S; Fregonese L; Larsson K; Hivert V; Westermark K; Naumann-Winter F; Stoyanova-Beninska V; Barišić I; Capovilla G; Magrelli A; Sepodes B
Nat Rev Drug Discov; 2019 Jul; 18(7):479-480. PubMed ID: 30940922
[No Abstract] [Full Text] [Related]
42. Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.
Giannuzzi V; Landi A; Bosone E; Giannuzzi F; Nicotri S; Torrent-Farnell J; Bonifazi F; Felisi M; Bonifazi D; Ceci A
BMJ Open; 2017 Sep; 7(9):e017358. PubMed ID: 28893754
[TBL] [Abstract][Full Text] [Related]
43. We need a "made in Canada" orphan drug framework.
McMillan HJ; Campbell C
CMAJ; 2017 Oct; 189(41):E1274-E1275. PubMed ID: 29038319
[No Abstract] [Full Text] [Related]
44. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.
Iskrov G; Miteva-Katrandzhieva T; Stefanov R
Health Policy; 2012 Nov; 108(1):10-8. PubMed ID: 22939047
[TBL] [Abstract][Full Text] [Related]
45. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.
Winstone J; Chadda S; Ralston S; Sajosi P
Orphanet J Rare Dis; 2015 Oct; 10():139. PubMed ID: 26511061
[TBL] [Abstract][Full Text] [Related]
46. [Orphan drugs--medications for patients with rare diseases].
Thielke D; Thyssen JP; Hansen BJ
Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
[TBL] [Abstract][Full Text] [Related]
47. Establishing rarity in the context of orphan medicinal product designation in the European Union.
Tsigkos S; Hofer MP; Sheean ME; Mariz S; Larsson K; Naumann-Winter F; Fregonese L; Sepodes B
Drug Discov Today; 2018 Mar; 23(3):681-686. PubMed ID: 28647377
[TBL] [Abstract][Full Text] [Related]
48. Affordable orphan drugs: a role for not-for-profit organizations.
Davies EH; Fulton E; Brook D; Hughes DA
Br J Clin Pharmacol; 2017 Jul; 83(7):1595-1601. PubMed ID: 28109021
[TBL] [Abstract][Full Text] [Related]
49. [Orphan drugs in France (2001-2005): access to information and characteristics].
Baumevieille M; Daveluy A; Aulois-Griot M; Haramburu F
Therapie; 2007; 62(1):9-16. PubMed ID: 17374342
[TBL] [Abstract][Full Text] [Related]
50. Brexit and rare diseases: big risk, bigger opportunity?
Hyry HI; Cox TM; Roos JC
Curr Med Res Opin; 2017 Apr; 33(4):783-784. PubMed ID: 28100081
[TBL] [Abstract][Full Text] [Related]
51. Access to orphan drugs - comparison across Balkan countries.
Pejcic AV; Iskrov G; Jakovljevic MM; Stefanov R
Health Policy; 2018 Jun; 122(6):583-589. PubMed ID: 29729905
[TBL] [Abstract][Full Text] [Related]
52. Rare diseases social epidemiology: analysis of inequalities.
Kole A; Faurisson F
Adv Exp Med Biol; 2010; 686():223-50. PubMed ID: 20824449
[TBL] [Abstract][Full Text] [Related]
53. Access to information supporting availability of medicines for patients suffering from rare diseases looking for possible treatments: the EuOrphan Service.
Stakisaitis D; Spokiene I; Juskevicius J; Valuckas KP; Baiardi P
Medicina (Kaunas); 2007; 43(6):441-6. PubMed ID: 17637514
[TBL] [Abstract][Full Text] [Related]
54. The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal Products.
Palomo GM; Pose-Boirazian T; Naumann-Winter F; Costa E; Duarte DM; Kalland ME; Malikova E; Matusevicius D; Vitezic D; Larsson K; Magrelli A; Stoyanova-Beninska V; Mariz S
Mol Ther; 2023 Dec; 31(12):3414-3423. PubMed ID: 37794679
[TBL] [Abstract][Full Text] [Related]
55. Principles for consistent value assessment and sustainable funding of orphan drugs in Europe.
Gutierrez L; Patris J; Hutchings A; Cowell W
Orphanet J Rare Dis; 2015 May; 10():53. PubMed ID: 25935555
[TBL] [Abstract][Full Text] [Related]
56. The European union policy in the field of rare diseases.
Montserrat Moliner A; Waligóra J
Public Health Genomics; 2013; 16(6):268-77. PubMed ID: 24503587
[TBL] [Abstract][Full Text] [Related]
57. Orphan drug development: an economically viable strategy for biopharma R&D.
Meekings KN; Williams CS; Arrowsmith JE
Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
[TBL] [Abstract][Full Text] [Related]
58. Orphan drugs revisited.
McCabe C; Tsuchiya A; Claxton K; Raftery J
QJM; 2006 May; 99(5):341-5; discussion 350-1. PubMed ID: 16504983
[No Abstract] [Full Text] [Related]
59. [Orphan Drugs: Underrated Opportunities for The Developers in Europe].
Tillet Y; Maillols-Perroy AC
Therapie; 2015; 70(4):351-7. PubMed ID: 25997721
[TBL] [Abstract][Full Text] [Related]
60. [The orphan preparations: international approaches and national regulation].
Foteeva AV; Rostova NB; Isupova AD; Gerbergagen ES
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2021 Nov; 29(6):1490-1497. PubMed ID: 34882322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
